Skip to main content
[Preprint]. 2023 Oct 9:rs.3.rs-3405677. [Version 1] doi: 10.21203/rs.3.rs-3405677/v1

Figure 5. UMCD6 enhances NK killing of human breast cancer cells in vivo.

Figure 5

A: Bioluminescence images of breast cancer MDA-MB-231 SCID/beige xenografts infused with 1×106 human NK cells and injected with 100 μg of antibodies (UMCD6 or IgG) at day 7. Control mice were not administered NK cells or antibodies. B: Bioluminescence imaging of MDA-MB-231 mice revealed a decrease in tumor growth in mice receiving NK cells and UMCD6 at day 3 and 8 compared to mice receiving NK cells and IgG control antibody. C: Survival rate was significantly increased in the UMCD6 group compared to both the IgG and control groups. UMCD6 vs. IgG, *p = 0.0246; UMCD6 vs. untreated, *p = 0.0389.